The targeted agents cetuximab and panitumumab, combined with chemotherapy, are an effective treatment for metastatic colon cancer, provided that certain mutations have not occurred in cancer cells (namely activating mutations in KRAS, NRAS or BRAF genes). Here, BRAF is linked to cancer.